Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1786 - Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study


09 Oct 2016


Poster display


Petra Pichler


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


P. Pichler1, N. Claes2, P. Mazza3, B. Zurawski4, P. Potocki5, E. Petru6, M. Šedivá7, J. Katolicka8, F. Lanza9, C. Fontaine10

Author affiliations

  • 1 Department Of Internal Medicine, University Clinic, 3100 - St. Pölten/AT
  • 2 Department Of Oncology, AZ St-Jan, Brugge/BE
  • 3 Hematology Unit, SS Annunziata Hospital, Taranto/IT
  • 4 Chemotherapy Unit, Oncology Center, Bydgoszcz/PL
  • 5 Department Of Clinical Oncology, University Hospital, Krakow/PL
  • 6 Department Of Obstetrics And Gynaecology, Medical University Graz, 8036 - Graz/AT
  • 7 Department Of Oncology, Nemocnice Na Bulovce, Prague/CZ
  • 8 Department Of Oncology, Nemocnice U sv. Anny, Brno/CZ
  • 9 Hematology Unit, Istituti Ospitalieri, Cremona/IT
  • 10 Department Of Oncology, UZ, Brussels/BE


Abstract 1786


Lipegfilgrastim (Lonquex®) is a long-acting glycopegylated G-CSF that was proven to be non-inferior with regards to duration of severe neutropenia compared with pegfilgrastim in breast cancer patients. The objective of this study was to evaluate effectiveness of lipegfilgrastim in everyday clinical practice in adult patients with different tumor types who are treated with cytotoxic chemotherapy.


This is a prospective non-interventional study. Patients with different tumor types treated with cytotoxic chemotherapy (CT), who received lipegfilgrastim in primary (PP) or secondary prophylaxis (SP) are included in this study. CT dose modifications and neutropenic and neutropenia-related events are recorded and analyzed. Evaluation of effectiveness following the first lipegfilgrastim-supported treatment cycle is presented here.


At the time of analysis (March 2016), a total of 621 patients have been included. Mean age of included patients was 59.2 ± 13.2 and 67.6% were female. Most patients had breast cancer (39.8%) and lymphoma (24.0%). Exposure to lipegfilgrastim has been documented for 507 patients. Data on CT dose modifications and neutropenic events following the first lipegfilgrastim-supported cycle were available for 409 and 448 patients, respectively. CT dose omissions were observed in 0.3% patients when lipegfilgrastim was applied in PP. No omissions were observed when it was applied in SP. CT dose delays were observed in 10.3% (PP) and 15.0% (SP) of patients and CT dose reductions in 5.2% (PP) and 7.5% (SP) of patients. Febrile neutropenia was recorded in 1.4% (PP) and 1.2% (SP) of patients, whereas severe neutropenia was recorded in 1.9% (PP) and 4.7% (SP) of patients. A total of 89 (17.6%) patients exposed to lipegfilgrastim reported at least one adverse drug reaction (ADR). The most common ADRs were myalgia, bone pain, and headache. Serious ADRs were reported by 25 (4.9 %) patients.


Lipegfilgrastim is effective and well tolerated in the real world setting administered either in PP or SP. Both effectiveness and safety data obtained in this study are in line with published data for lipegfilgrastim.

Clinical trial identification


Legal entity responsible for the study

Teva Pharmaceuticals


Teva Pharmaceuticals


E. Petru: Honoraria from Teva, Roche, Amgen, Sandoz. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings